Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer | Zendy

Gregory L. Branigan | Zendy; Maira Soto | Zendy; Leigh Neumayer | Zendy; Kathleen E. Rodgers | Zendy; Roberta Dı́az Brinton | Zendy

Open Access

Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer

Author(s) -

Gregory L. Branigan,

Maira Soto,

Leigh Neumayer,

Kathleen E. Rodgers,

Roberta Dı́az Brinton

Publication year - 2020

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.1541

Subject(s) - breast cancer , medicine , cancer , oncology , cohort , retrospective cohort study , population , hormone therapy , cohort study , gynecology , environmental health

Key Points Question Is hormone-modulating therapy associated with neurodegenerative disease in women with breast cancer? Findings In this cohort study of 57 843 perimenopausal- to postmenopausal-aged women with breast cancer, exposure to hormone-modulating therapy (tamoxifen and aromatase inhibitors, especially exemestane) was associated with a significant decrease in the number of women who received a diagnosis of neurodegenerative disease, most specifically Alzheimer disease. Meaning With the increased life expectancy seen after treatment, therapy selection for breast cancer should include a careful discussion of the risks and benefits of each treatment option that may be associated with a reduced risk of neurodegenerative disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research